Cardiac Contractility Modulation Device and Subcutaneous Implantable Cardioverter Defibrillator Combination: A New Hope for Heart Failure Patients with Low Ejection Fraction and Narrow QRS Complex

<p>Heart failure is a common cardiovascular disease with a high morbidity and mortality despite advances in medical and devicerelated management. Cardiac resynchronization therapy (CRT) which is also known as biventricular pacing has proven to be an effective treatment in heart failure [1-6]....

Full description

Saved in:
Bibliographic Details
Main Authors: Bandar Al-Ghamdi (Author), Azam Shafquat (Author), Yaseen Mallawi (Author)
Format: Book
Published: Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications, 2016-05-25.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-2976_000024
042 |a dc 
100 1 0 |a Bandar Al-Ghamdi  |e author 
700 1 0 |a  Azam Shafquat  |e author 
700 1 0 |a Yaseen Mallawi  |e author 
245 0 0 |a Cardiac Contractility Modulation Device and Subcutaneous Implantable Cardioverter Defibrillator Combination: A New Hope for Heart Failure Patients with Low Ejection Fraction and Narrow QRS Complex 
260 |b Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,   |c 2016-05-25. 
520 |a <p>Heart failure is a common cardiovascular disease with a high morbidity and mortality despite advances in medical and devicerelated management. Cardiac resynchronization therapy (CRT) which is also known as biventricular pacing has proven to be an effective treatment in heart failure [1-6]. However, CRT is  generally recommended for patients in sinus rhythm and prolonged QRS complex (≥ 120 ms) with left bundle branch block (LBBB), or a QRS complex width of ≥ 150 ms in the absence of LBBB [6]. On the other hand, only 30-40% of all heart failure patients show such a prolonged QRS complex [7,8] and therefore the 60-70% of patients who have a normal QRS complex cannot be treated with CRT. Furthermore, around 30% of the patients eligible for CRT treatment do not respond to CRT [7,8].</p> 
540 |a Copyright © Bandar Al-Ghamdi et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-2976.000024  |z Connect to this object online.